NCT07185841View on ClinicalTrials.gov

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

January 7, 2029

Conditions

Wet Age-related Macular Degeneration (AMD)

Interventions

DRUG

HX9428 tablet

Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..

Trial Locations (1)

100010

RECRUITING

Beijing Hospital, Beijing

All Listed Sponsors

lead

Fujian Haixi Pharmaceuticals Co., Ltd.

INDUSTRY

NCT07185841 - Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD) | Biotech Hunter | Biotech Hunter